Cyclerion Therapeutics Stock Today
| CYCN Stock | USD 3.05 0.45 12.86% |
Performance0 of 100
| Odds Of DistressOver 83
|
Cyclerion Therapeutics is selling at 3.05 as of the 23rd of April 2024; that is -12.86 percent decrease since the beginning of the trading day. The stock's open price was 3.5. Cyclerion Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Cyclerion Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 28th of February 2023 and ending today, the 23rd of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 2nd of April 2019 | Category Healthcare | Classification Health Care |
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system diseases. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts. The company has 2.71 M outstanding shares of which 22.05 K shares are currently shorted by private and institutional investors with about 9.25 trading days to cover. More on Cyclerion Therapeutics
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Cyclerion Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Cyclerion Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Cyclerion Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| President | Regina Graul | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering Cyclerion Therapeutics report their recommendations after researching Cyclerion Therapeutics' financial statements, talking to executives and customers, or listening in on Cyclerion Therapeutics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Cyclerion Therapeutics. The Cyclerion consensus assessment is calculated by taking the average forecast from all of the analysts covering Cyclerion Therapeutics. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the key indicators related to Cyclerion Therapeutics' liquidity, profitability, solvency, and operating efficiency, Cyclerion Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in May. Financial strength of Cyclerion Therapeutics is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cyclerion Therapeutics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Cyclerion Therapeutics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Cyclerion Therapeutics' financial leverage. It provides some insight into what part of Cyclerion Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cyclerion Therapeutics (CYCN) is traded on NASDAQ Exchange in USA. It is located in 245 First Street, Riverview II, Cambridge, MA, United States, 02142 and employs 1 people. Cyclerion Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 8.27 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Cyclerion Therapeutics's market, we take the total number of its shares issued and multiply it by Cyclerion Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Cyclerion Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 2.71 M outstanding shares of which 22.05 K shares are currently shorted by private and institutional investors with about 9.25 trading days to cover.
Cyclerion Therapeutics currently holds about 30.32 M in cash with (21.25 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.7.
Check Cyclerion Therapeutics Probability Of Bankruptcy
Ownership AllocationCyclerion Therapeutics retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months.
Check Cyclerion Ownership Details
Cyclerion Stock Price Odds Analysis
Contingent on a normal probability distribution, the odds of Cyclerion Therapeutics jumping above the current price in 90 days from now is about 63.06%. The Cyclerion Therapeutics probability density function shows the probability of Cyclerion Therapeutics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Cyclerion Therapeutics has a beta of -0.8161 suggesting as returns on the benchmark increase, returns on holding Cyclerion Therapeutics are expected to decrease at a much lower rate. During a bear market, however, Cyclerion Therapeutics is likely to outperform the market. Additionally, cyclerion Therapeutics has an alpha of 0.0469, implying that it can generate a 0.0469 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
Based on a normal probability distribution, the odds of Cyclerion Therapeutics to move above the current price in 90 days from now is about 63.06 (This Cyclerion Therapeutics probability density function shows the probability of Cyclerion Stock to fall within a particular range of prices over 90 days) .
Cyclerion Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Cyclerion Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Cyclerion Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Cyclerion Therapeutics' value.| Instituion | Recorded On | Shares | |
| Group One Trading, Lp | 2023-12-31 | 540 | |
| Royal Bank Of Canada | 2023-12-31 | 330 | |
| Advisor Group Holdings, Inc. | 2023-12-31 | 187 | |
| Wells Fargo & Co | 2023-12-31 | 15.0 | |
| Northwestern Mutual Wealth Management Co | 2023-12-31 | 1.0 | |
| Captrust Financial Advisors | 2023-09-30 | 0.0 | |
| Acadian Asset Management Llc | 2023-12-31 | 0.0 | |
| Jane Street Group, Llc | 2023-09-30 | 0.0 | |
| Rhumbline Advisers | 2023-12-31 | 0.0 | |
| Slate Path Capital Lp | 2023-12-31 | 357.9 K | |
| Mfn Partners Management, Lp | 2023-12-31 | 169.5 K |
Cyclerion Therapeutics Historical Income Statement
Cyclerion Therapeutics Income Statement is one of the three primary financial statements used for reporting Cyclerion's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Cyclerion Therapeutics revenue and expense. Cyclerion Therapeutics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Cyclerion Therapeutics' Interest Expense is very stable compared to the past year. As of the 23rd of April 2024, Selling General Administrative is likely to grow to about 16.2 M, while Total Revenue is likely to drop 0.00. View More FundamentalsCyclerion Stock Against Markets
Picking the right benchmark for Cyclerion Therapeutics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Cyclerion Therapeutics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Cyclerion Therapeutics is critical whether you are bullish or bearish towards Cyclerion Therapeutics at a given time. Please also check how Cyclerion Therapeutics' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Cyclerion Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Performance Analysis Now
Performance AnalysisCheck effects of mean-variance optimization against your current asset allocation |
| All Next | Launch Module |
Cyclerion Therapeutics Corporate Management
Elected by the shareholders, the Cyclerion Therapeutics' board of directors comprises two types of representatives: Cyclerion Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cyclerion. The board's role is to monitor Cyclerion Therapeutics' management team and ensure that shareholders' interests are well served. Cyclerion Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cyclerion Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Todd Milne | Senior Innovation | Profile | |
| Cheryl Gault | Chief Officer | Profile | |
| Jessica Rennekamp | Associate Communications | Profile | |
| Christopher Winrow | Sr Lead | Profile | |
| Jennifer Chickering | Director Strategy | Profile | |
| Rhonda Chicko | Chief Officer | Profile |
How to buy Cyclerion Stock?
Before investing in Cyclerion Therapeutics, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Cyclerion Therapeutics. To buy Cyclerion Therapeutics stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Cyclerion Therapeutics. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Cyclerion Therapeutics stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Cyclerion Therapeutics stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Cyclerion Therapeutics stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Cyclerion Therapeutics, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Cyclerion Stock please use our How to Invest in Cyclerion Therapeutics guide.
Already Invested in Cyclerion Therapeutics?
The danger of trading Cyclerion Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Cyclerion Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Cyclerion Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Cyclerion Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Cyclerion Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cyclerion Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cyclerion Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cyclerion Therapeutics Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclerion Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. To learn how to invest in Cyclerion Stock, please use our How to Invest in Cyclerion Therapeutics guide.Note that the Cyclerion Therapeutics information on this page should be used as a complementary analysis to other Cyclerion Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Complementary Tools for Cyclerion Stock analysis
When running Cyclerion Therapeutics' price analysis, check to measure Cyclerion Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cyclerion Therapeutics is operating at the current time. Most of Cyclerion Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cyclerion Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cyclerion Therapeutics' price. Additionally, you may evaluate how the addition of Cyclerion Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |
Is Cyclerion Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclerion Therapeutics. If investors know Cyclerion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclerion Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.39) | Revenue Per Share 0.586 | Quarterly Revenue Growth 0.141 | Return On Assets (0.38) | Return On Equity (1.16) |
The market value of Cyclerion Therapeutics is measured differently than its book value, which is the value of Cyclerion that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclerion Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cyclerion Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclerion Therapeutics' market value can be influenced by many factors that don't directly affect Cyclerion Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cyclerion Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cyclerion Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclerion Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.